Tag: Obefazimod
Abivax announces new results on its flagship product obefazimod – 02/10/2023 at 6:19 p.m.
(AOF) – Abivax announced today that three datasets on its lead drug candidate, obefazimod, will be presented at the United European Week of Gastroenterology (UEG) meeting, October 14-17, 2023, in…
Abivax highlights its clinical development program for obefazimod in ulcerative colitis
By Claude Leguilloux Published on 02/10/2023 at 6:49 p.m. Photo credit © Abivax (Boursier.com) — Abivax SA, a…
Abivax announces new results on its flagship product obefazimod
(AOF) – Abivax announced today that three datasets on its lead drug candidate, obefazimod, will be presented at the United European Week of Gastroenterology (UEG) meeting, October 14-17, 2023, in…
Abivax: Publication of an expert opinion in the JCC journal on obefazimod as a therapeutic option for the treatment of patients with UC. – 05/02/2023 at 6:10 p.m.
ABIVAX press release Publication of an expert opinion in the journal JCC on obefazimod as a therapeutic option for the treatment of patients with UC. The authors of the expert…
Abivax to present data from blood samples from UC patients treated with obefazimod at the 18th ECCO Congress
By Hector Chaunu Published on 02/14/2023 at 6:46 p.m. Photo credit © Abivax (Boursier.com) — Abivax a…
Abivax: FDA approval for pediatric development plan with obefazimod
By Olivier Cheilan Published on 2022-12-20 at 6:21 p.m. Photo credit © Abivax …
Abivax: FDA approval for a study on obefazimod – 12/20/2022 at 6:28 pm
(CercleFinance.com) – Abivax announces today that the FDA (Food & Drug Administration) has approved the pediatric initial study plan (iPSP) for the clinical development of obefazimod for the treatment of…
Abivax: FDA approval for a study on obefazimod
(CercleFinance.com) – Abivax announces today that the FDA (Food & Drug Administration) has approved the pediatric initial study plan (iPSP) for the clinical development of obefazimod for the treatment of…
Abivax includes the first patient in the United States in its global phase 3 program with obefazimod in ulcerative colitis. – 10/11/2022 at 6:06 p.m.
ABIVAX press release Abivax includes the first patient in the United States in its global phase 3 program with obefazimod in ulcerative colitis. First patient included in the United States…
Abivax includes a first patient in its phase 3 program with obefazimod (rectocolitis) – 10/11/2022 at 18:17
(AOF) – The clinical phase 3 biotechnology company Abivax announces that it has enrolled the first patient in the United States in its global phase 3 program with Obefazimod in…
Abivax: Abstract on phase 2b results of obefazimod selected for poster presentation at UEG Week 2022. – 09/27/2022 at 18:05
ABIVAX press release Abivax: Abstract of Obefazimod phase 2b results selected for poster presentation at UEG Week Congress 2022. Interim analysis on safety and efficacy after 48 weeks of treatment…
ABIVAX: The phase 3 clinical program with Obefazimod in ulcerative colitis is progressing after the approval of the IRB in the United States. – 04/08/2022 at 18:05
ABIVAX press release ABIVAX: The phase 3 clinical program with Obefazimod in ulcerative colitis is progressing after the approval of the IRB in the United States. The protocols for the…